Financial Services, Funds, Innovations, Latvia, Medicine, Technology

Deep Longevity, Inc. provides a high-quality growth asset and a key platform for expanding into the emerging field of longevity medicine. It can be used to develop comprehensible artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. These systems for longevity medicine help physicians to make better decisions on interventions that may slow or reverse aging processes. And Deep Longevity, Inc.'s deep haematological clocks can be explored as a predictive tool for the analysis of COVID-19 positive patients.

Deep Longevity, Inc. provides Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" - it provides a universal multifactorial measure of human biological age to the global network of advanced physicians and researchers. The aging clocks were created in a research partnership with one of the most prominent longevity organizations in the world, Human Longevity, Inc. 

Deep Longevity, Inc. closed a Series A funding round at the end of June 2020. LongeVC has been joined in a round by some of the most worldwide well-known venture capitalists specializing in biotechnology, longevity, and artificial intelligence ("AI") - ETP Ventures, Human Longevity, and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, co-founder of Oculus, Michael Antonov, and other AI and biotechnology expert investors.

Deep Longevity, Inc. is a previously undisclosed investment of the first early-stage investment fund LongeVC. Now the company has been fully acquired by Regent Pacific for USD 3.79 mln through issuing Consideration Shares and further strengthening the shareholder base with high-level longevity and wellness biotechnology investors and entrepreneurs. With this acquisition, Regent Pacific Group Limited (Hong Kong stock code: 00575), a specialist healthcare, wellness, and life sciences investment group intend to develop the largest integrated platform for longevity biotechnology and aging research.

"Our team welcomes this acquisition and is proud to have participated in one of the testimonies to the enormous future potential that the longevity industry has to offer. It is a unique deal for the Baltic area, and we are determined to use our expertise to screen and invest in similar deals globally," explains LongeVC Partner Sergejs Jakimovs. 

Currently, the new fund LongeVC is being set up. The total amount of the money available from the fund is estimated to be USD 35 mln. "We are targeting seed-stage and pre-A funding round companies as there are limited opportunities worldwide to get investments at these stages. LongeVC will have a strong focus on companies working with solutions in longevity and biotechnology. This is the focus that will drive our interest and not the geographical perspective. LongeVC is already discussing investments with companies from Europe, Asia, and the US," says Jakimovs. He also emphasizes that top-notch experts in the longevity field are going to be available to startups. LongeVC is already collaborating with the co-founder of Oculus Michael Antonov, founder of Deep Longevity, Inc. and adjunct professor at the Buck Institute for Research on Aging Alex Zhavoronkov (Ph.D.) as well as many others.